Helicobacter Pylori Eradication to Prevent Gastric Cancer
Status:
Unknown status
Trial end date:
2020-05-01
Target enrollment:
Participant gender:
Summary
Gastric cancer is the fourth most common type of cancer and the second leading cause of
cancer-related death in the world. In China, more than 390,000 new patients are diagnosed
with gastric cancer and more than 300,000 patients are killed by the terrible disease
annually. Although gastric cancer has a multifactorial etiology, infection with H. pylori is
highly associated with gastric carcinogenesis. Therefore, eradication of H. pylori infection
appears to reduce the risk of gastric cancer. However, several recent controlled
interventional trials by H. pylori eradication to prevent gastric cancer have yielded
disappointing results. The exact effect of H.pylori eradication on prevention of gastric
cancer is unclear up to now. To clarify this problem, the investigators conducted a
prospective, randomized, double-blind, placebo-controlled, population-based study to
determine whether H pylori eradication would reduce the incidence of gastric cancer in a
high-risk population in China.